We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BALL:NYSEBall Corporation Analysis

Data as of 2026-05-23 - not real-time

$56.51

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ball Corporation delivered a strong Q1 2026, posting revenue of $3.6 billion, a 16.3% year‑over‑year increase. Non‑GAAP EPS came in at $0.94, topping consensus estimates by 11.3%. The company also announced a quarterly dividend of $0.80, yielding about 1.42% with a modest 23% payout ratio. On the price side, the stock trades at $56.51, comfortably above the computed support level of $54.58. Technical gauges show a neutral trend, an RSI of 40.8 indicating slight undervaluation, and a bearish MACD histogram of –0.10. Volume has been on a decreasing trajectory, suggesting reduced short‑term buying pressure.
Analysts assign a “Buy” consensus with a median price target of $71.5, implying roughly 25% upside from current levels. The consensus fair‑value estimate of $70.86 aligns with that upside and places the stock in the undervalued category relative to market price. A low computed beta of 0.40 and a 30‑day volatility of 29.9% point to modest systematic risk but notable price swings. The dividend appears sustainable given a 23% payout and solid operating cash flow of $1.15 billion. Sector‑specific risks are moderate, while regulatory and geographic exposures remain medium. Overall, the combination of earnings momentum, attractive valuation and defensive dividend profile supports a buy stance across horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Q1 earnings beat
  • price near support
  • decreasing volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • analyst upside potential
  • robust revenue growth
  • sustainable dividend

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • low beta and defensive profile
  • stable operating cash flow
  • strong industry positioning

Key Metrics & Analysis

Financial Health

Revenue Growth16.30%
Profit Margin6.86%
P/E Ratio16.5
ROE16.79%
ROA4.70%
Debt/Equity145.54
P/B Ratio2.7
Op. Cash Flow$1.1B
Free Cash Flow$403.5M

Technical Analysis

TrendNeutral
RSI40.8
Support$54.58
Resistance$62.35
MA 20$58.17
MA 50$59.97
MA 200$55.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair Value$10.73
Target Price$70.79
Upside/Downside25.26%
GradeUndervalued
TypeBlend
Dividend Yield1.42%

Risk Assessment

Beta0.40
Volatility29.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.